Three specific parasites are officially classified as Group 1 carcinogens, meaning there is sufficient evidence that they cause cancer in humans. But the viral internet claim that parasites are the hidden cause of cancer generally, or that deworming yourself can cure or prevent the disease, is not supported by evidence. The real science here is narrower, stranger, and in some ways more interesting than the conspiracy version.
Which Parasites Actually Cause Cancer
The International Agency for Research on Cancer (IARC), the cancer-evaluation arm of the World Health Organization, has placed three parasites in its highest risk category. Two are liver flukes: Opisthorchis viverrini, found mainly in Southeast Asia, and Clonorchis sinensis, common in East Asia. Both are linked to cholangiocarcinoma, a cancer of the bile ducts. The third is Schistosoma haematobium, a blood fluke endemic to parts of Africa and the Middle East, which is linked to squamous cell carcinoma of the bladder.1PubMed Central. The role of liver fluke invasion in the pathogenesis of cholangiocarcinoma People typically acquire these parasites by eating raw or undercooked freshwater fish (for the liver flukes) or through contact with contaminated freshwater (for the blood fluke).
These are not rare curiosities. In Thailand’s northeast provinces, where raw fish dishes are traditional, cholangiocarcinoma occurs at some of the highest rates in the world. In sub-Saharan Africa, bladder cancer driven by S. haematobium follows the geographic footprint of the parasite’s snail hosts. Recent estimates suggest that infections overall account for roughly 15 to 20 percent of all cancers in low- and middle-income countries, with parasitic worms representing the third leading group of cancer-causing pathogens after viruses and bacteria.2PubMed Central. Parasitic Infections and Carcinogenesis: Molecular Mechanisms, Immune Modulation, and Emerging Therapeutic Strategies Globally, about two million new cancer cases per year (around 16 percent) are attributable to infections of all kinds, including viruses, bacteria, and parasites.3PubMed Central. Infection and cancer: global distribution and burden of diseases
To be clear, most cancers worldwide are not caused by any infection at all, let alone a parasite. The leading drivers remain tobacco, diet, obesity, UV exposure, and inherited genetic mutations. But in specific populations with heavy, chronic parasite exposure, the contribution is real and significant.
How a Worm Turns Tissue Cancerous
Parasites do not cause cancer the way a virus like HPV does, by injecting genetic instructions into your cells. The process is slower and messier. When a worm or its eggs lodge in tissue, the immune system mounts a response. Immune cells flood the area, releasing inflammatory molecules and reactive oxygen species to kill the invader. If the infection is cleared quickly, the damage heals. But these parasites often persist for years or even decades, and that sustained cycle of tissue damage, inflammation, and repair is where the trouble starts.
Chronic inflammation generates a steady stream of molecules that can directly damage DNA, breaking strands and modifying the chemical bases that encode genetic information. If those mutations accumulate in genes that control cell growth or suppress tumors, a cell can begin to grow uncontrollably.2PubMed Central. Parasitic Infections and Carcinogenesis: Molecular Mechanisms, Immune Modulation, and Emerging Therapeutic Strategies Alongside this, repeated injury and scarring (fibrosis) physically remodel the tissue, creating an environment more hospitable to cancer.4PubMed. DNA damage induced by parasitic infections in humans and animals
Some parasites go further than just provoking inflammation. The liver fluke O. viverrini secretes a growth factor called Ov-GRN-1 that directly stimulates human bile duct cells to multiply. In laboratory experiments, even tiny concentrations of this protein caused significant cell proliferation, mimicking the effect of human growth factors.5PubMed Central. A Granulin-Like Growth Factor Secreted by the Carcinogenic Liver Fluke, Opisthorchis viverrini, Promotes Proliferation of Host Cells When researchers suppressed the gene encoding Ov-GRN-1, the proliferative effect on bile duct cells was inhibited.6PubMed Central. Suppression of Ov-grn-1 encoding granulin of Opisthorchis viverrini inhibits proliferation of biliary epithelial cells The fluke is, in a sense, actively pushing its host’s cells toward abnormal growth.
Clonorchis sinensis operates through a similar playbook. Research has shown that chronic infection drives epigenetic changes in the bile duct lining, alterations not to the DNA sequence itself but to how genes are switched on and off, along with precancerous lesion formation.7PubMed Central. Clonorchis sinensis and cholangiocarcinoma: molecular mechanisms and biomarker advances Meanwhile, S. haematobium eggs lodged in bladder tissue appear to produce proteins that interact with key cancer-related pathways in the host, including binding to the tumor suppressor p53 in a way that could disable its protective function.8SciEnggJ. Computational docking analysis of Schistosoma haematobium egg derived proteins: Implications of IPSE/α-1 and serpin in bladder cancer development
A striking recent study tracked the genomic timeline of fluke-associated bile duct cancer and found that the earliest cancer-driving mutations appeared on average around age 30, two to four decades before patients were actually diagnosed with cancer.9PubMed Central. Natural history of liver fluke infection underpins epidemiological patterns of biliary cancer The long fuse underscores how parasite-driven cancer is a slow accumulation of genetic damage, not a sudden event.
When Parasites and Viruses Work Together
Parasite-driven cancer risk does not exist in a vacuum. In many parts of the world where parasitic infections are common, hepatitis B and C viruses also circulate widely. When someone is co-infected with Schistosoma species and hepatitis B or C, the clinical course is typically much worse than either infection alone. Co-infected individuals have prolonged viral carriage, faster liver fibrosis, more cirrhosis, and higher mortality.10PubMed. Coinfection of Schistosoma Species with Hepatitis B or Hepatitis C Viruses Since cirrhosis is a major pathway to liver cancer, co-infection effectively accelerates the progression toward malignancy.
A similar dynamic has been reported with cervical cancer. S. haematobium can infect genital tissue, and case reports suggest that when the parasite damages the cervical lining, it creates an opening for human papillomavirus (HPV) to establish persistent infection. In at least one well-documented case, long-term follow-up showed that schistosomiasis alone did not cause abnormal cervical cell growth; it was the combination with HPV that drove progression toward cancer.11PubMed. Association of Schistosoma haematobium and human papillomavirus in cervical cancer: a case report The parasite’s role was as a cofactor, traumatizing the tissue and suppressing local immunity in a way that favored the virus.
Emerging Suspects
Beyond the three IARC-classified parasites, researchers are investigating whether other organisms contribute to cancer risk. Cryptosporidium, a waterborne parasite best known for causing diarrheal illness, has attracted attention after studies found it at surprisingly high rates in colorectal cancer patients. One study from Iran found Cryptosporidium in over 40 percent of colorectal cancer patients, compared with about 13 percent of healthy controls.12Parasite Epidemiology and Control. High prevalence of Cryptosporidium infection in Iranian patients suffering from colorectal cancer In an animal model, C. parvum infection caused epithelial damage, cellular abnormalities, and, in the majority of examined tissue samples, changes classified as intramucosal carcinoma.13PubMed Central. Azithromycin Mitigates Experimental Cryptosporidiosis-Driven Ileocecal Adenocarcinoma by Modulating Autophagy, Apoptosis, and PI3K/AKT Signaling
The catch is that correlation does not equal causation. Cancer patients often have weakened immune systems, making them more susceptible to opportunistic infections like Cryptosporidium. It remains an open question whether the parasite is helping drive the cancer or simply thriving because the cancer (and its treatment) has weakened the host.14PubMed Central. Cryptosporidium and Colon Cancer: Cause or Consequence? This is a genuinely unresolved chicken-and-egg problem in the field.
The Tapeworm That Gave a Man Its Own Cancer
One of the strangest case reports in all of oncology appeared in the New England Journal of Medicine in 2015. A Colombian man with HIV arrived at a hospital with tumors in his lymph nodes and lungs. Biopsies showed nests of small, rapidly dividing cells that behaved like cancer but were bizarrely tiny, about ten times smaller than human cancer cells. DNA analysis identified the cells as belonging to Hymenolepis nana, the dwarf tapeworm, one of the most common human tapeworm infections worldwide.15PubMed. Malignant Transformation of Hymenolepis nana in a Human Host
The tapeworm’s own cells had undergone malignant transformation and then invaded human tissue, essentially giving the man its cancer. The worm’s cells carried mutations in genes associated with cancer, much like those seen in human tumors. The patient’s profoundly suppressed immune system (from untreated HIV) likely allowed this to happen, since a healthy immune system would normally eliminate both the parasite and any abnormal cells it produced. This case remains the only well-documented instance of a parasite transmitting its cancer to a human, and it illustrates how the intersection of parasites and cancer can take truly unexpected forms.
The Fenbendazole and Ivermectin Phenomenon
If you have heard about parasites and cancer on social media, it is probably not because of liver flukes. A different narrative has taken hold online: that antiparasitic drugs like fenbendazole, mebendazole, and ivermectin can treat or cure cancer. The story often begins with Joe Tippens, an Oklahoma man who credited fenbendazole (a dog dewormer) with his recovery from late-stage lung cancer, and has been amplified by alternative health communities ever since.
There is a kernel of legitimate science here, which is part of why the claims have proven so sticky. Mebendazole, a close relative of fenbendazole that is approved for human use, has shown genuinely interesting anticancer properties in laboratory and animal studies. It interferes with cell structures that dividing cancer cells depend on, inhibits the formation of new blood vessels that tumors need to grow, and appears to enhance the effects of standard chemotherapy and radiation in preclinical models.16PubMed Central. Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature It can cross the blood-brain barrier, which makes it a candidate for research into brain cancers, and several clinical trials are now exploring its effects.17PubMed Central. Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers Albendazole, another member of the same drug family, has shown similar activity in lab settings, though concerns about bone marrow toxicity at higher doses have made mebendazole the more attractive candidate for ongoing trials.18PubMed Central. Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
The gap between lab results and a proven cancer treatment is enormous, though. Most of the data on these drugs comes from cell cultures and animal models. Clinical evidence in actual human patients remains thin. One small trial of mebendazole in patients with advanced cancer found only one partial response out of nine patients, with most showing disease progression.19Pharmacy Times. From Farm to Pharmacy: Controversial Antiparasitics in Cancer Care Ivermectin, the other drug frequently promoted online, has an even weaker evidence base for cancer treatment, with studies almost entirely confined to cell lines and animal models. Thousands of drugs look promising in a petri dish and fail in people. That is not a reason to dismiss the research, but it is a reason to be deeply skeptical of anyone selling antiparasitic drugs as a cancer cure today.
And the mechanism has nothing to do with killing parasites that “cause” cancer. These drugs happen to interfere with cellular machinery (like tubulin, a protein that cells need to divide) that is shared between parasites and human cancer cells. It is a coincidence of biology, not evidence that cancer is secretly a parasitic disease.
Parasites as Potential Cancer Immunotherapy Tools
In a strange twist, some researchers are studying whether parasites themselves could be engineered to fight cancer. Toxoplasma gondii, the parasite best known for infecting cats and occasionally causing problems in pregnant women, is a potent activator of the immune system. Attenuated (weakened) strains of the parasite have been tested in mouse models of melanoma, lung cancer, colon cancer, and pancreatic cancer. In these experiments, injecting the modified parasite near tumors activated immune cells, particularly the cytotoxic T cells that are responsible for killing cancer cells, and inhibited tumor growth.20Journal for ImmunoTherapy of Cancer. Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
When combined with checkpoint inhibitor drugs (the same class of immunotherapy drugs that have transformed treatment for melanoma and other cancers), the effect was even stronger. In a pancreatic cancer model, the combination of an attenuated T. gondii strain and an anti-PD-1 antibody reduced the population of immune-suppressing cells in the tumor environment while boosting cancer-killing T cells.21PubMed Central. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model This is all preclinical, and deliberately infecting cancer patients with even a weakened parasite raises obvious safety questions. But the concept that parasites can both cause and potentially treat cancer, depending on the context, captures something genuinely interesting about the relationship between the immune system, infections, and malignancy. A systematic review has noted that while chronic parasitic infections tend to promote tumors through inflammation and immune suppression, acute or engineered parasite exposure can produce the opposite effect by jolting the immune system into action.22PubMed Central. The dual role of parasites and parasite-derived products in cancer biology: a systematic review of in vitro and in vivo evidence
Why Treatment Itself Can Be Complicated
If parasite-driven cancer is caused by decades of chronic infection, you might assume that treating the infection early would eliminate the risk. The picture is muddier than that. Praziquantel, the standard drug used to treat liver fluke infections, kills the parasites effectively. But there is a concerning signal in the epidemiological data: repeated courses of praziquantel may actually be associated with higher odds of certain types of bile duct cancer. One study found that people who had taken praziquantel three or more times had roughly four times the odds of developing intrahepatic cholangiocarcinoma compared to those who had never been treated.23PubMed. Association between Repeated Praziquantel treatment and Papillary, and Intrahepatic Cholangiocarcinoma
This does not mean the drug causes cancer. A plausible explanation is that when the drug kills large numbers of flukes inside the bile ducts, the mass die-off releases a burst of inflammatory material and parasite proteins into already-damaged tissue, potentially accelerating the process toward malignancy. People who need repeated treatment also tend to be those with the heaviest and most persistent infections, so the association may partly reflect worse underlying disease. A systematic meta-analysis of the available evidence found no statistically significant overall association between praziquantel use and cholangiocarcinoma, though it pooled only a small number of studies.24PubMed. Association between praziquantel and cholangiocarcinoma in patients infected with Opisthorchis viverrini: a systematic review and meta-analysis The uncertainty here highlights a genuine challenge in managing parasite-associated cancer risk: you cannot simply deworm your way out of the problem, because by the time someone has been reinfected repeatedly over decades, significant genetic damage may already have accumulated.
Parasites and Cancer in Other Animals
The parasite-cancer connection is not unique to humans. In dogs, Spirocerca lupi, a nematode that lodges in the esophagus, causes inflammatory nodules that progress to sarcomas (connective tissue cancers) in roughly a quarter of infected animals.25PubMed Central. Spirocerca lupi Proteomics and Its Role in Cancer Development: An Overview of Spirocercosis-Induced Sarcomas and Revision of Helminth-Induced Carcinomas The progression from benign nodule to malignant tumor follows a pattern remarkably similar to what is seen in humans with fluke-associated cancers: chronic tissue damage, inflammation, fibrosis, and eventually neoplastic transformation.26PubMed. Spirocerca lupi induced oesophageal neoplasia: Predictors of surgical outcome Canine spirocercosis has been useful as a comparative model because the timeline from infection to tumor is shorter in dogs, making it easier to study the stepwise progression.
A Nobel Prize for a Wrong Answer
The idea that parasites cause cancer is older than most people realize, and it has an embarrassing chapter in the history of science. In 1926, Danish scientist Johannes Fibiger won the Nobel Prize in Physiology or Medicine for his claim that a roundworm, Spiroptera neoplastica (later renamed Gongylonema neoplasticum), caused stomach cancer in rats. Fibiger had fed cockroaches containing the worm larvae to rats and observed what he believed were stomach tumors. The Nobel committee awarded him the prize for demonstrating that a parasite could cause cancer, a groundbreaking idea at the time.27Annals of Internal Medicine. Johannes Fibiger and his Nobel Prize for the hypothesis that a worm causes stomach cancer
Later work revealed that what Fibiger had observed were not true cancers but rather noncancerous tissue changes caused by vitamin A deficiency in his laboratory rats. The worms provoked irritation and abnormal cell growth, but the growths were not malignant. Fibiger’s hypothesis was essentially wrong in its specifics, though decades later, the broader concept that chronic infection can lead to cancer would be vindicated in far more rigorous ways with the parasites described throughout this article. His Nobel remains one of the most frequently cited examples of a prestigious award given for findings that did not hold up.